Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Improved insurance coverage likely drove increased adoption of Semglee (insulin glargine-yfgn) rather than its status as an interchangeable biosimilar of Lantus, according to new research published in ...

THE sale of Massy Distribution (Jamaica) Limited (MDJL) to Acado Limited continues to remain on pause as the Fair Trading ...

Arising from: Marks JB (2008) How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? Nat Clin Pract ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to ...

Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes using its continuous glucose monitors.  | Dexcom said Smart Basal is the ...

Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, ...

If low glucose events occur, Dexcom Smart Basal lowers the user’s insulin dose recommendation by the amount set by their ...

Central Virginia  Pharmaceutical giants AstraZeneca, Eli Lilly & Co. and Merck & Co. have committed a cumulative $120 million ...

Shaw said Biocon’s growth trajectory over the next five years will be “very exciting,” with even larger opportunities emerging beyond 2030 as big-ticket biologics go off patent.

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich' ...